

UNITED STATE DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
09/314,698	05/19/99	PERRIN		S	14791-501(AR
•		HM12/0828	コ		EXAMINER
MINTZ LEVIN COHN FERRIS				EINSMA	ANN, J
GLOVSKY AND				ART UNIT	PAPER NUMBER
ONE FINANCIO BOSTON MA 0:				1655	8
				DATE MAILED:	: 08/28/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

•	Application No.	Applicant(s)
Office Action Comme	09/314,698	PERRIN ET AL.
Office Action Summary	Examiner	Art Unit
	Juliet C. Einsmann	1655
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet wit	h the correspondence address
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION	EPLY IS SET TO EXPIRE <u>3</u> M DN.	ONTH(S) FROM
 Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this come of the period for reply specified above is less than thirty (30 be considered timely. If NO period for reply is specified above, the maximum state communication. Failure to reply within the set or extended period for reply vistatus 	imunication. I) days, a reply within the statutory mitutory period will apply and will expire	nimum of thirty (30) days will SIX (6) MONTHS from the mailing date of this
1)⊠ Responsive to communication(s) filed on	07 July 2000	
	This action is non-final.	
3) Since this application is in condition for all closed in accordance with the practice un	owance except for formal mat	tters, prosecution as to the merits is D. 11, 453 O.G. 213.
Disposition of Claims		
4)⊠ Claim(s) <u>1-25</u> is/are pending in the applica	ition.	
4a) Of the above claim(s) is/are with	ndrawn from consideration.	
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-25</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claims are subject to restriction an	d/or election requirement.	
Application Papers		
9) The specification is objected to by the Exar	miner.	
10) The drawing(s) filed on is/are object	ed to by the Examiner.	
11) The proposed drawing correction filed on _	is: a) approved b)	disapproved.
12) The oath or declaration is objected to by th	e Examiner.	
Priority under 35 U.S.C. § 119		
13) Acknowledgment is made of a claim for for	eign priority under 35 U.S.C.	§ 119(a)-(d).
a) ☐ All b) ☐ Some * c) ☐ None of the CER	TIFIED copies of the priority of	documents have been:
1. received.		
2. received in Application No. (Series 0	Code / Serial Number)	
3. received in this National Stage applic	cation from the International B	ureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a		• • • • • • • • • • • • • • • • • • • •
14) Acknowledgement is made of a claim for do	omestic priority under 35 U.S.	C. & 119(e).
Attachment(s)		
15) ☑ Notice of References Cited (PTO-892) 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948 17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No	3) 19) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)

U.S. Patent and Trademark Office PTO-326 (Rev. 3-98)

Art Unit: 1655

DETAILED ACTION

- 1. This action is written in response applicant's correspondence submitted 7/7/2000, paper number 7. Claims 1, 2, 7, 8, 11, 12, 15, 18, 21, and 22 have been amended and claim 25 has been added. Claims 1-25 are pending. Applicant's amendments and arguments have been thoroughly reviewed, but are not persuasive for the reasons that follow. Any rejections not reiterated in this action have been withdrawn as being obviated by the amendment of the claims. This action is FINAL.
- 2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 103

3. Claims 1-14, 21, and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kayne et al. (WO 9843088) in view of Gress *et al.* (Mammalian Genome 3: 609-612, 1992).

This rejection is reiterated for claims 1-14 and 21, and applied to newly added claim 25.

Kayne et al. teach a method for identifying and isolating non-redundant nucleic acid fragments which comprises the steps of: providing a library containing undefined nucleic acid sequences (p. 2, lines 9-10), hybridizing said library to a collection of defined nucleic acid sequences (p. 2, line 8), wherein the defined nucleic acid sequences have been previously sequenced and/or are of known origin (p. 3, line 17-18), recovering non-hybridized nucleic acid sequences (p. 2, lines 10-11), and sequencing the non-hybridized nucleic acid sequences (see abstract and p. 9, lines 9-10). In the method taught by Kayne et al., the collection of defined nucleic acid sequences is bound to a surface (p.2, line 8), wherein the surface may be an array (p.

Art Unit: 1655

5, line 31), and the preferred surface for such and array is glass (p. 6, line 12). The method teaches that the sequences to be hybridized to the array should be labeled to permit detection of the DNA which hybridizes to the immobilized sequences (p. 7, line 16-17).

With respect to claims 2-7, 14, and 17, Kayne et al. teach the library of unknown fragments can include gene or gene fragments, may be a random cDNA library, may be genes from an organ, or may be set of RNAs (p. 6, lines 26-28). With respect to claims 8-9, and step (a) of claims 11-14, Kayne teach that a library may also contain PCR products from genomic libraries (p. 4, line 2). With respect to claim 10, Kayne teaches that the label used can be fluorescence, radioactivity, photoactiviation, biotinylation, energy transfer or the like (p. 7, lines 17-19). With respect to claim 13, in the method of Kayne et al., nucleic acids on a grid are exposed to a library containing undefined nucleic acid sequences, and this library is considered to be a set of pooled labeled probes (p. 2, lines 9-10).

The method of Kayne et al. differs from the claimed method because in the method of Kayne et al. the collection of defined nucleic acid sequences is bound to a surface, and in the claimed method the undefined nucleic acid sequences are bound a microarray. Gress et al. teach a method for hybridization fingerprinting of high-density cDNA-library arrays with cDNA pools in which a random cDNA library is hybridized to a microarray with the help of a robotic device (p. 609). Gress et al. teach that the spotting cDNAs onto a microarray allows for the screening of thousands of clones at one time, and also provides a method which is adaptable for automated analysis.

Art Unit: 1655

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Kayne et al. so as to have spotted the library of random nucleic acids on the microarray in order to have provided an improved method for isolating and identifying non-redundant nucleic acids since concerning large scale DNA characterization projects Gress et al. state, "As we have shown in our work with genomic libraries, such large-scale projects can most easily be performed with library arrays spotted at high clone density with a robotic device..." (p. 613).

With respect to claims 11-14 Kayne in view of Gress do not explicitly teach step (f) of the instantly claimed invention, which comprises repeating the hybridization, detection, and identification of the probes which did not hybridize in order to identify additional sequences. However, this step would also have been obvious to a practitioner of ordinary skill in the art for the reasons that follow. Kayne et al. do teach that in some cases it is desired to repeat some steps in the method to control the size and content of the resulting subtraction library (p. 8, lines 7-9), and they specifically teach that "it is preferred that multiple rounds of hybridization are carried out" (p. 8, line 13). Considering this teaching of Payne et al., it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have repeated any of the steps in the method for the added benefit of increasing the amount of sequences detected. Further, "selection of any order of performing process steps is prima facie obvious in the absence of new or unexpected results" (MPEP 2144.04). In the instant case, applicant is simply choosing to repeat already disclosed steps, and this would have been obvious to one of ordinary skill in the art. With respect to claim 25, when such repetition it would have been

Art Unit: 1655

further *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have included a probe that recognized the most recently sequenced nucleic acid when the steps were repeated since the methods of Kayne *et al.* are specifically designed to identify unknown sequences.

Finally, the examiner notes that these claims have different preambles, but substantially the same method steps, and a preamble is generally not accorded any patentable weight where it merely recites the purpose of a process or the intended use of a structure, and where the body of the claim does not depend on the preamble for completeness but, instead, the process steps or structural limitations are able to stand alone. In the case of these claims, the preamble was only directed to the purpose of the process, the steps could stand alone and did not depend on the preamble for completeness, and therefore, the different preambles were not given strong consideration in analysis of the claims (see MPEP 2111.02).

Response to applicant's remarks

Applicant argues that neither Kayne nor Gress, alone or in combination teach or suggest a step in which a fragment in a population of random, immobilized nucleic acids be determined. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). As noted above, the teachings of Kayne differ from those of Gress only in that in the method of Kayne the unknown sequences are not immobilized on the array. Gress does indeed overcome this deficiency of Kayne. Gress

Art Unit: 1655

teaches that for the screening of large groups of unknown sequences, spotting the unknown sequences onto an array provides a method which is beneficial both because it allows for the screening of thousands of clones at one time and also because the use of an array offers the possibility of automated analysis. This teaching by Gress is sufficient to motivate a change in the method taught by Kayne in which the unknown fragments are immobilized and the known probes are in solution. Such a switch would result in the method of Kayne being carried out such that the non-hybridized immobilized fragments would be sequenced.

NEW GROUNDS OF REJECTION AND OBJECTION NECESSITATED BY APPLICANT'S AMENDMENT OF THE CLAIMS

4. Claim 11 is objected to because of the following informalities:

In step (e) of this claim, the brackets in the amendment are unclear. That is, "[determining the [identity of the DNA] sequence" is missing a bracket. It appears that the bracket prior to the word "determining" is in error because it appears that the "determining the" portion of the claim language is intended to be part of the claim as amended.

The final step recites a "random ample" instead of a "random sample".

Appropriate correction is required.

5. Claims 15-17 and 22-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pinkel et al (US Patent 5690894) in view of Schena *et al.* (Science (1995) 270:467-470).

Pinkel et al. disclose a method for enrichment and/or isolation of DNA sequences that are unique to a population which comprises the steps of: amplifying random samples of nucleic acid

Art Unit: 1655

fragments, such as by using Alu or degenerate oligonucleotide primers in a PCR reaction (Col. 16, lines 64-65), immobilizing the amplification products as an array to form a biosensor (Col. 17, lines 7-14), exposing the biosensor to labeled nucleic acid probes from two sources (Col. 15, lines 40-47) wherein the labeled nucleic acids can be derived from genomic samples (Col. 16, lines 37-40) or from mRNA (Col. 16, lines 44-45), detecting hybridization of nucleic acids from the first and second source (Col. 15, lines 60-65), and then determining the identity of the hybridized molecules using clones which have been previously mapped which is an analytical approach for determining the identity of the nucleic acid fragment (Col. 17, lines 46-54). Pinkel et al. teach that this method can be used to detect sequences which are under-represented in a sample or over-represented in a sample by comparing the strength of the hybridization signals from the two nucleic acid populations (Col. 15, lines 18-23).

Pinkel *et al.* do not teach methods in which the random samples of nucleic acid fragments are immobilized on a coated glass surface.

Schena et al. teach methods for monitoring gene expression patterns using a microarray spotted onto a glass microscope slide (p. 467). Schena et al. further teach the use of two-color hybridization experiments on the microarray (469). It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have spotted the random nucleic acid fragments taught by Pinkel et al. onto a glass slide as taught by Schena et al. The ordinary practitioner would have been motivated to have made such a substitution in order to create a high capacity system for monitoring the presence of genes since Schena et al. teach that "because of the small format and high density of the arrays, hybridization volumes of 2

Art Unit: 1655

microliters could be used that enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA."

6. Claims 18-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pinkel et al. in view of Schena *et al.* in view of Maslyn et al.

Pinkel et al. teach a method for discovery of DNA sequences which comprises the steps of: amplifying random samples of nucleic acid fragments, such as by using Alu or degenerate oligonucleotide primers in a PCR reaction (Col. 16, lines 64-65), immobilizing the amplification products as an array to form a biosensor (Col. 17, lines 7-14), hybridizing labeled probes to the biosensor (Col. 15, lines 40-47) wherein the labeled nucleic acids can be derived from genomic samples (Col. 16, lines 37-40) or from mRNA (Col. 16, lines 44-45), detecting hybridization of the labeled probes to the biosensor (Col. 15, lines 60-65), and then determining the identity of the hybridized molecules using clones which have been previously mapped which is an analytical approach for determining the identity of the nucleic acid fragment (Col. 17, lines 46-54). Pinkel et al. teach that this method can be used to detect sequences which are underrepresented in a sample or over-represented in a sample by comparing the strength of the hybridization signals from the two nucleic acid populations (Col. 15, lines 18-23), and Pinkel specifically teaches that some hybridization signals will be stronger than others, and it is a necessary fact that if some hybridization signals are stronger there must also be weaker signals. Stringency is an routinely optimizable parameter and Pinkel teaches that standard techniques for hybridization are to be used (Col. 20, lines 1-2).

Art Unit: 1655

Pinkel *et al.* do not teach methods in which the random samples of nucleic acid fragments are immobilized on a coated glass surface.

Schena *et al.* teach methods for monitoring gene expression patterns using a microarray spotted onto a glass microscope slide (p. 467). Schena *et al.* further teach the use of two-color hybridization experiments on the microarray (469). It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have spotted the random nucleic acid fragments taught by Pinkel *et al.* onto a glass slide as taught by Schena *et al.* The ordinary practitioner would have been motivated to have made such a substitution in order to create a high capacity system for monitoring the presence of genes since Schena *et al.* teach that "because of the small format and high density of the arrays, hybridization volumes of 2 microliters could be used that enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA."

Neither Pinkel *et al.* not Schena *et al.* teach a step in which the obtained DNA sequences are compared to other DNA sequences.

Maslyn et al. teach that a "cluster" is a group of clones related to one another by sequence homology (Col. 7, lines 43-44), and that determining a cluster is achieved by comparing the sequence of against a library or database of sequences (Col. 12, lines 12-16).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have included the comparison step of Maslyan et al. in the method taught by Pinkel et al. Maslyn specifically teaches that this is a useful method "to look for homologous, and presumably functionally related sequences in other tissues or samples." This is particularly

Art Unit: 1655

useful in the context of method of Pinkel et al. since Pinkel et al. expressly compares two different cell types and is interested in the relationship between the cell types (Col. 15).

Conclusion

- 7. No claims are allowed.
- 8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Juliet C. Einsmann whose telephone number is (703) 306-5824.

The examiner can normally be reached on Monday through Thursday, 7:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones can be reached on (703) 308-1152. The fax phone numbers for the

Art Unit: 1655

organization where this application or proceeding is assigned are (703) 308-4242 and (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

JEFFREY FREDMAN PRIMARY EXAMINER

Juliet C. Einsmann Examiner Art Unit 1655

August 24, 2000